

LITERATUR

1. *Abood GJ, Nickoloff BJ, Gamelli RL (2008)* Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? *J Burn Care Res* 29: 269–276
2. *Araki Y et al (2009)* Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. *Am J Ophthalmol* 147: 1004–1011
3. *Arevalo JM et al (2000)* Treatment of toxic epidermal necrolysis with cyclosporin A. *J Trauma* 48: 473–478
4. *Azad N, Zafar S, Khan A (2009)* Successful treatment of ligneous conjunctivitis with topical cyclosporine and heparin. *J AAPOS* 13: 519–520
5. *Bauer M et al (2016)* Conjunctivitis lignosa. *Ophthalmologie* 113: 416–419
6. *Ballow M, Mendelson L (1980)* Specific immunoglobulin E antibodies in tear secretions of patients with vernal conjunctivitis. *J Allergy Clin Immunol* 66: 112–118
7. *Balding SD et al (1996)* Cicatricial pemphigoid autoantibodies react with multiple sites on the BP180 extracellular domain. *J Invest Dermatol* 106: 141–146
8. *Beck LA et al (2014)* Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med* 371: 130–139
9. *Bekou V et al (2005)* Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. *J Invest Dermatol* 124: 732–740
10. *Bielory L et al (2007)* Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders. *MedGenMed* 9: 35
11. *Bhol KC et al (2000)* The autoantibodies to alpha 6 beta 4 integrin of patients affected by ocular cicatricial pemphigoid recognize predominantly epitopes within the large cytoplasmic domain of human beta 4. *J Immunol* 165: 2824–2829
12. *Bilkhu PS, Wolffsohn JS, Naroo SA (2012)* A review of non-pharmacological and pharmacological management of seasonal and perennial allergic conjunctivitis. *Cont Lens Anterior Eye* 35: 9–16
13. *Blauvelt A et al (2017)* Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet* 389: 2287–2303
14. *Borchers AT et al (2008)* Stevens-Johnson syndrome and toxic epidermal necrolysis. *Autoimmun Rev* 7: 598–605
15. *Bowling B (2017)* *Kanskis klinische Ophthalmologie*. Elsevier, München
16. *Bron AJ et al (2017)* TFOS DEWS II pathophysiology report. *Ocul Surf* 15: 438–510
17. *Calonge M, Herreras JM (2007)* Clinical grading of atopic keratoconjunctivitis. *Curr Opin Allergy Clin Immunol* 7: 442–445
18. *Chan LS (2001)* Mucous membrane pemphigoid. *Clin Dermatol* 19: 703–711
19. *Chigbu DI (2009)* The management of allergic eye diseases in primary eye care. *Cont Lens Anterior Eye* 32: 260–272
20. *Craig JP et al (2017)* TFOS DEWS II Definition and Classification Report. *Ocul Surf* 15: 276–283
21. *Egan CA et al (2001)* Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. *Lancet* 357: 1850–1851
22. *Egan CA et al (2003)* Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations. *Medicine (Baltimore)* 82: 177–186
23. *Elder MJ, Bernauer W (1994)* Cryotherapy for trichiasis in ocular cicatricial pemphigoid. *Br J Ophthalmol* 78: 769–771
24. *Elder MJ et al (1996)* Progression of disease in ocular cicatricial pemphigoid. *Br J Ophthalmol* 80: 292–296
25. *Elhers WH, Donshik PC (2008)* Giant papillary conjunctivitis. *Curr Opin Allergy Clin Immunol* 8: 445–449
26. *Eshtiaghi P, Gooderham MJ (2018)* Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. *Core Evid* 13: 13–20
27. *Foster CS (1986)* Cicatricial pemphigoid. *Trans Am Ophthalmol Soc* 84: 527–663
28. *Foster CS, Rice BA, Dutt JE (1991)* Immunopathology of atopic keratoconjunctivitis. *Ophthalmology* 98: 1190–1196
29. *Friedlaender, MH (2011)* Ocular allergy. *Curr Opin Allergy Clin Immunol* 11: 477–482
30. *Frings A, Geerling G, Schargus M (2017)* *Red Eye: A guide for non-specialists*. *Dtsch Arztebl Int* 114: 302–312
31. *Fukuda K et al (2009)* Critical role of IgE-dependent mast cell activation in a murine model of allergic conjunctivitis. *J Allergy Clin Immunol* 124: 827–833 e2
32. *Guglielmetti S, Dart JK, Calder V (2010)* Atopic keratoconjunctivitis and atopic dermatitis. *Curr Opin Allergy Clin Immunol* 10: 478–485
33. *Heinz C et al (2002)* Conjunctivitis lignosa bei Typ-I-Plasminogenmangel – Kasuistik mit Literaturübersicht. *Klin Monatsbl Augenheilkd* 219: 156–158
34. *Hiremath M et al (2011)* Heparin in the long-term management of ligneous conjunctivitis: a case report and review of literature. *Blood Coagul Fibrinolysis* 22: 606–609
35. *John T et al (2002)* Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. *Ophthalmology* 109: 351–360
36. *Johansson SG et al (2004)* Revised nomenclature for allergy for global use: Report of the nomenclature review committee of the world allergy organization, October 2003. *J Allergy Clin Immunol* 113: 832–836
37. *Kallen C et al (2003)* Atopische Keratokonjunktivitis: Wahrscheinlich ein Risikofaktor für die Entstehung von Bindehautkarzinomen. *Ophthalmologie* 100: 808–814
38. *Kirtschig G et al (1995)* Anti-basement membrane autoantibodies in patients with anti-epiligrin cicatricial pemphigoid bind the alpha subunit of laminin 5. *J Invest Dermatol* 105: 543–548

39. Knop E, Knop N, Frings A et al (2018) Das Trockene Auge: Update anhand des DEWS-II-Reports Teil I: Definition, Klassifikation und Epidemiologie. *Z prakt Augenheilkd* 39: 477–487
40. Kruse FE et al (2003) Klassifikation der Erkrankungen der Augenoberfläche. Teil 1. *Ophthalmologe* 100: 899–915
41. Kumari S et al (2001) Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin. *Invest Ophthalmol Vis Sci* 42: 379–385
42. Kuonen A et al (2013) Ligneous conjunctivitis in a young patient with homozygous K19E plasminogen gene mutation: a diagnostic and therapeutic challenge. *Klin Monatsbl Augenheilkd* 230: 346–348
43. La Rosa M et al (2013) Allergic conjunctivitis: a comprehensive review of the literature. *Ital J Pediatr* 39: 18
44. Leonard JN et al (1988) Immunofluorescent studies in ocular cicatricial pemphigoid. *Br J Dermatol* 118: 209–217
45. Leonardi A (2005) Emerging drugs for ocular allergy. *Expert Opin Emerg Drugs* 10: 505–520
46. Leonardi A et al (2006) Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. *Acta Ophthalmol Scand* 84: 406–410
47. Leonardi A et al (2006) Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. *Acta Ophthalmol Scand* 84: 406–410
48. Leonardi A, Motterle L, Bortolotti M (2008) Allergy and the eye. *Clin Exp Immunol* 153 (Suppl 1): 17–21
49. Letko E et al (2004) A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies. *Clin Immunol* 111: 303–310
50. Leverkus M et al (1999) Antiepileptin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring autoimmune subepidermal bullous diseases? *Arch Dermatol* 135: 1091–1098
51. Lonjou C et al (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenet Genomics* 18: 99–107
52. Maier P, Lapp T, Reinhard T (2017) Augenbeteiligung bei atopischer Dermatitis: Klinische Aspekte und Therapie *Ophthalmologe* 114: 514–524
53. McGill JJ et al (1998) Allergic eye disease mechanisms. *Br J Ophthalmol* 82: 1203–1214
54. Mehta R, Shapiro AD (2008) Plasminogen deficiency. *Haemophilia* 14: 1261–1268
55. Meire FM, Claerhout I, Kestelyn PH (2000) Use of mitomycin C and r-tPA for the management of conjunctival membrane and cataracts in a child with conjunctivitis lignosa. *Br J Ophthalmol* 84: 1204–1205
56. Messmer EM (2005) Okuläre Allergien. *Ophthalmologe* 102: 527–543; Quiz 544
57. Messmer EM (2009) Therapeutische Optionen bei Keratoconjunctivitis vernalis. *Ophthalmologe* 106: 557–562
58. Messmer EM (2009) Therapeutische Optionen bei Keratoconjunctivitis vernalis. *Ophthalmologe* 106: 557–562
59. Messmer EM (2015) Pathophysiologie, Diagnostik und Therapie des trockenen Auges. *Dtsch Arztebl Int* 112: 71–81; Quiz 82
60. Meyer-Ter-Vehn T (2016) Nicht infektiöse Bindehauterkrankungen. *Klin Monatsbl Augenheilkd* 233: 547–564
61. Mockenhaupt M et al (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. *J Invest Dermatol* 128: 35–44
62. Montan PG et al (1999) Vernal keratoconjunctivitis in a Stockholm ophthalmic centre-epidemiological, functional, and immunologic investigations. *Acta Ophthalmol Scand* 77: 559–563
63. Mukasa Y, Craven N (2008) Management of toxic epidermal necrolysis and related syndromes. *Postgrad Med J* 84: 60–65
64. Murakami H et al (1998) Analysis of antigens targeted by circulating IgG and IgA autoantibodies in 50 patients with cicatricial pemphigoid. *J Dermatol Sci* 17: 39–44
65. Neff AG, Turner M, Mutasim DF (2008) Treatment strategies in mucous membrane pemphigoid. *Ther Clin Risk Manag* 4: 617–626
66. O'Brien TP (2013) Allergic conjunctivitis: an update on diagnosis and management. *Curr Opin Allergy Clin Immunol* 13: 543–549
67. Ono SJ, Abelson MB (2005) Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. *J Allergy Clin Immunol* 115: 118–122
68. Oyama N et al (2006) Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. *Br J Dermatol* 154: 90–98
69. Pergantou H et al (2011) Management of ligneous conjunctivitis in a child with plasminogen deficiency. *Eur J Pediatr* 170: 1333–1336
70. Pleyer U, Leonardi A (2015) Keratoconjunctivitis vernalis. *Ophthalmologe* 112: 177–189; Quiz 190–191
71. Poon AC et al (2001) Autologous serum eye-drops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. *Br J Ophthalmol* 85: 1188–1197
72. Rahi A et al (1977) Keratoconus and coexisting atopic disease. *Br J Ophthalmol* 61: 761–764
73. Reinhard T, Ruzicka T, Sundmacher R (1999) Pathogenese, Klinik und Therapie der Augenbeteiligung bei Atopie. *Ophthalmologe* 96: 473–488
74. Robinson JW et al (2006) Conjunctival mucoepithelioid carcinoma in a patient with ocular cicatricial pemphigoid and a review of the literature. *Surv Ophthalmol* 51: 513–519

75. Roujeau JC *et al* (1995) Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. *N Engl J Med* 333: 1600–1607
76. Rowsey JJ, Macias-Rodriguez Y, Cukrowski C (2004) A new method for measuring progression in patients with ocular cicatricial pemphigoid. *Arch Ophthalmol* 122: 179–184
77. Rumelt S *et al* (2006) Intraoperative enoxaparin minimizes inflammatory reaction after pediatric cataract surgery. *Am J Ophthalmol* 141: 433–437
78. Samarawickrama C, Chew S, Watson S (2015) Retinoic acid and the ocular surface. *Surv Ophthalmol* 60: 183–195
79. Saw VP *et al* (2008) Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes. *Ophthalmology* 115: 253–261 e1
80. Schmidt E *et al* (2001) Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. *Br J Dermatol* 145: 778–783
81. Schmidt E *et al* (2008) Schleimhautpemphigoid mit okulärer Beteiligung. Teil I: Klinik, Pathogenese und Diagnostik. *Ophthalmologie* 105: 285–297; Quiz 298
82. Schott D *et al* (1998) Therapy with a purified plasminogen concentrate in an infant with ligneous conjunctivitis and homozygous plasminogen deficiency. *N Engl J Med* 339: 1679–1686
83. Schroder K *et al* (2014) Die saisonale und perenniale allergische Rhinokonjunktivitis. *Klin Monatsbl Augenheilkd* 231: 496–504
84. Schroeter AL (1987) Pemphigoid and malignancy. *Clin Dermatol* 5: 60–63
85. Schuster V, Seregard S (2003) Ligneous conjunctivitis. *Surv Ophthalmol* 48: 369–388
86. Simpson EL, Akinlade B, Ardeleanu M (2017) Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. *N Engl J Med* 376: 1090–1091
87. Sitaru C, Zillikens D (2005) Mechanisms of blister induction by autoantibodies. *Exp Dermatol* 14: 861–875
88. Sotozono C (2007) New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. *Ophthalmology* 114: 1294–1302
89. Tefs K *et al* (2006) Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patients. *Blood* 108: 3021–3026
90. Thaci D *et al* (2016) Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. *Lancet* 387: 40–52
91. Tyagi S *et al* (1996) Ocular cicatricial pemphigoid antigen: partial sequence and biochemical characterization. *Proc Natl Acad Sci USA* 93: 14714–14719